CD19 specific Chimeric Antigen Receptor T Cell therapy(Nationwide Children'S Hospital)

N/A

Report date: 2023/03/28 20:00:38

Base Information

Drug NameCD19 specific Chimeric Antigen Receptor T Cell therapy(Nationwide Children'S Hospital)
Drug Alias NameCD19 hsCAR-T(Nationwide Children'S Hospital)CD19-specific chimeric antigen receptor engineered T cells(Nationwide Children'S Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A